Organovo (ONVO) Stock Price, News & Analysis

Company Overview

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.66 to $15.24
• 52-Week Range: N/A
• Volume: 243,634 shs
• Average Volume: 617,505 shs
• Market Capitalization: $3.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONVO Stock Analysis - Frequently Asked Questions

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings results on Wednesday, February, 19th. The medical research company reported ($2.28) EPS for the quarter, topping the consensus estimate of ($2.52) by $0.24. The medical research company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative trailing twelve-month return on equity of 346.26% and a negative net margin of 10,151.64%.

When did Organovo's stock split?

Organovo shares reverse split on the morning of Friday, March 21st 2025.The 1-12 reverse split was announced on Wednesday, March 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organovo investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Brainstorm Cell Therapeutics (BCLI), AST SpaceMobile (ASTS) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 8/23/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONVO
• CIK: 1497253
• Web: www.organovo.com
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 20
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($10.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.67 million
• Net Margins: -10,151.64%
• Pretax Margin: -10,150.00%
• Return on Equity: -346.26%
• Return on Assets: -187.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $122 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,701,000
• Free Float: 14,794,000
• Market Cap: $3.47 million
• Optionable: Optionable
• Beta: 1.13